TD Cowen lowered the firm’s price target on Iqvia (IQV) to $174 from $245 and keeps a Hold rating on the shares. The firm updated its model following Q4 results and guidance and said while they believe there are risks from AI, it’s important to note they will play out over the long term and the impact on CROs isn’t fully clear.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA: Solid 2026 Outlook but AI Disruption Risks Justify Hold Rating and Lowered Valuation
- Iqvia price target lowered to $240 from $265 at Morgan Stanley
- Iqvia announces collaboration with Duke Clinical Research Institute
- IQVIA Holdings Earnings Call Signals AI-Driven Growth
- Iqvia price target lowered to $240 from $280 at UBS